The Technical Analyst
Aytu BioScience Inc [AYTU]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Aytu BioScience Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $2.79
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15.53 mill |
| EPS: | -4.01 |
| P/E: | -0.700 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 5.57 mill |
| Avg Daily Volume: | 0.0210 mill |
| RATING 2024-04-19 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.700 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.700 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.62 - 2.96 ( +/- 6.13%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-31 | Pyszczymuka Greg | Buy | 208 | Common Shares |
| 2024-03-31 | Pyszczymuka Greg | Sell | 208 | Restricted Stock Units |
| 2023-12-31 | Pyszczymuka Greg | Buy | 209 | Common Shares |
| 2023-12-31 | Pyszczymuka Greg | Sell | 209 | Restricted Stock Units |
| 2023-09-30 | Pyszczymuka Greg | Buy | 208 | Common Shares |
| INSIDER POWER |
|---|
| 30.89 |
| Last 94 transactions |
| Buy: 33 552 785 | Sell: 39 056 468 |
Forecast:
16:00 - $2.78
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.78
Forecast 2: 16:00 - $2.78
Forecast 3: 16:00 - $2.78
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $2.79 (0.00% ) |
| Volume | 0.0069 mill |
| Avg. Vol. | 0.0210 mill |
| % of Avg. Vol | 32.94 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AYTU
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AYTU
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Last 10 Buy Signals
Latest Press Releases
2024-04-03 09:00:00 - Press Release
Aytu Biopharma To Present At The Emerging Growth Conference On April 4, 2024
Webcasted presentation to take place at 4:40 p.m. eastern time denver, co / accesswire / april 3, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its ceo, josh disbrow, will be participating in the emerging growth conference.
2024-02-14 16:05:00 - Press Release
Aytu Biopharma Reports Record Adhd Revenue And Operating Income During Fiscal 2024 Second Quarter
Q2 2024 operating income of $2.4 million q2 2024 net loss of $0.2 million and adjusted ebitda1 of $5.1 million q2 2024 rx segment net revenue of $18.7 million, net income of $0.7 million, and adjusted ebitda of $5.5 million q2 2024 adhd portfolio net revenue up 49% compared to q2 2023 $19.5 million cash balance at december 31, 2023 company to host conference call and webcast today, february 14, 2024 at 4:30 p.m. eastern time denver, co / accesswire / february 14, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.
2024-02-07 16:15:00 - Press Release
Aytu Biopharma To Report Second Quarter Fiscal 2024 Financial And Operational Results On February 14, 2024
Denver, co / accesswire / february 7, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended december 31, 2023, after the market close on wednesday, february 14, 2024. the company has scheduled a conference call and webcast that same day, wednesday, february 14, 2024, at 4:30 p.m.
2024-01-23 09:00:00 - Press Release
Aytu Biopharma To Participate In A Fireside Chat At The Lytham Partners 2024 Investor Select Conference On February 1, 2024
Denver, co / accesswire / january 23, 2024 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced that josh disbrow, ceo, will participate in a fireside chat and host one-on-one meetings with investors at the lytham partners 2024 investor select conference taking place virtually on february 1, 2024. company webcast the webcasted fireside chat will take place at 11:45am et on thursday, february 1, 2024.
2023-11-30 08:00:00 - Press Release
Aytu Biopharma To Present On The Emerging Growth Conference On December 7, 2023
Webcasted presentation to take place at 1:10pm et denver, co / accesswire / november 30, 2023 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its ceo, josh disbrow, will be participating in the emerging growth conference on december 7, 2023. mr. disbrow will conduct a presentation and subsequently open the floor to questions.
Latest News
2024-04-03 09:00:00 - Accesswire
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Webcasted presentation to take place at 4:40 p.m. Eastern time DENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.
2024-02-14 22:52:09 - Seeking Alpha
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
2024-02-07 16:15:00 - Accesswire
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, February 14, 2024, at 4:30 p.m.
2023-11-14 19:30:27 - Seeking Alpha
Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Robert Blum Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023. Joining us on today's call is Aytu's CEO, Josh Disbrow, and the company's Chief Financial Officer, Mark Oki.
2023-11-07 16:15:00 - Accesswire
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after the market close on Tuesday, November 14, 2023. The Company has scheduled a conference call that same day, Tuesday, November 14, 2023, at 4:30 pm ET, to review the results.
2023-10-09 16:15:00 - Accesswire
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023. Company Webcast The Company's webcast presentation will be available for viewing at 7:00am ET on Tuesday, October 17, 2023, on the Company's website at https://investors.aytubio.com/ or https://wsw.com/webcast/lytham9/aytu/2072440.
2023-09-28 11:55:43 - PennyStocks
Best Penny Stocks? 4 Hot Stocks With News This Week
What do you consider the best penny stocks? Are they the ones exploding higher within a single session?
2023-09-27 19:01:03 - Seeking Alpha
Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2023 Earnings Call Transcript September 27, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call.
2023-09-21 20:25:00 - Accesswire
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
ENGLEWOOD, CO / ACCESSWIRE / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the market close on Wednesday, September 27, 2023. The Company has scheduled a conference call that same day, Wednesday, September 27, 2023, at 4:30 pm ET, to review the results.
2023-09-13 08:00:00 - Accesswire
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
ENGLEWOOD, CO / ACCESSWIRE / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the LD Micro Main Event XVI Conference, being held on October 3-5, 2023, at Luxe Sunset Boulevard Hotel in Los Angeles. Management will present on Wednesday, October 4th at 10:00am PT.